Understanding your genetic context can support a more informed conversation about probiotic selection, timing, and whether microbiome support aligns with your individual physiology during GLP-1 treatment
By this definition, semaglutide is a peptide: it is a 31-amino-acid analog of human GLP-1, modified at positions 8 (Aib substitution) and 34 (arginine to lysine), with a C18 fatty diacid chain attached at lysine 26 via a linker
Without evidence demonstrating safety, responsible physicians decline this approach
Neither approach is inherently better - they serve different budgets, different medical situations, and different risk tolerances - but they shouldn't be evaluated as substitutes for one another
The exponential error model or additive error model was used for assessing the inter-study variability, which is shown in formulas (dg): where 1, i and 2, i represent the variabilities of inter-study, which are added into E max or ET 50 when available and they are assumed to be distributed normally and the distribution characteristics are a mean of 0 and variance of 1, i 2 and 2, i 2 , respectively
There are currently 5-10 million people on a branded GLP-1 medication, but there is an estimated 50-60 million who are clinically eligible to receive Wegovy and have insurance coverage for it, and of those, millions could purchase it for a copay of less than $100/month